General Information of Drug (ID: DM47B2O)

Drug Name
ISIS 32035 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DM47B2O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY-292223 DML36ZE Discovery agent N.A. Investigative [2]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 Discovery agent N.A. Investigative [2]
3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol DM54MDH Discovery agent N.A. Investigative [3]
ISIS 32014 DMF5SK8 Discovery agent N.A. Investigative [1]
ISIS 32024 DMPKGIU Discovery agent N.A. Investigative [1]
ISIS 32000 DM0O9WM Discovery agent N.A. Investigative [1]
ISIS 32021 DMISB5V Discovery agent N.A. Investigative [1]
ISIS 32003 DM7EVQX Discovery agent N.A. Investigative [1]
ISIS 32028 DMATWDO Discovery agent N.A. Investigative [1]
ISIS 32039 DMY1R0Q Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3K p110 beta messenger RNA (PIK3CB mRNA) TT9H4P3 PK3CB_HUMAN Not Available [1]

References

1 US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression.
2 LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
3 Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44.